-
Abbott to acquire Cerevel and its neuroscience pipeline
On December 7th, Abbey and Cerevel Therapeutics announced a final agreement - Abbey will acquire Cerevel Therapeutics and its neuroscience pipeline. Cerevel's pipeline consists of multiple clinical s ... -
Tianjing Biotechnology management welcomes another 'major overhaul': the shadow of CD47 target failure still lingers in the innovation pipeline with only three remaining CD47 targets
On July 15th, IMAB. US announced that its board of directors has appointed Fu Wei as the chairman of the board. Fu Wei will replace Pamela M. Klein, who will step down as director and interim chairma ...